HBIOX — Hartford International Opportunities Hls Fund
Data updated: 2026-05-22
HBIOX — Hartford International Opportunities Hls Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Developed ex-US Multi-Cap / All-Cap Blend / Core Equity · $801.89M AUM · 1.01% expense ratio · 21.1% 1-yr return. From SEC regulatory filings.
HBIOX Fund Overview
HBIOX — Hartford International Opportunities Hls Fund is a US mutual fund managed by Hartford Series Fund INC, categorised as Developed ex-US Multi-Cap / All-Cap Blend / Core Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Hartford Series Fund INC
- Category: Developed ex-US Multi-Cap / All-Cap Blend / Core Equity
- Assets under management: $801.89M
- 1-year return: 21.1%
- Ticker: HBIOX
- SEC CIK: 0001053425
- SEC series ID: S000003213
- Share class ID: C000008613
HBIOX Holdings
Top 10 holdings of Hartford International Opportunities Hls Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Taiwan Semiconductor Manufacturing Co Ltd | 6.08% |
| Shell PLC | 2.69% |
| ASML Holding NV | 2.69% |
| Tencent Holdings Ltd | 2.47% |
| SK hynix Inc | 2.14% |
| AstraZeneca PLC | 1.93% |
| Royal Bank of Canada | 1.93% |
| Orange SA | 1.76% |
| Allianz SE | 1.74% |
| AIA Group Ltd | 1.74% |
HBIOX Portfolio Allocation
Asset-class allocation of Hartford International Opportunities Hls Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 96.8% |
| Cash & Equivalents | 0.6% |
HBIOX Performance
Total returns for HBIOX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -1.1% |
| 1 year | 21.1% |
| 3 years (annualised) | 13.7% |
| 5 years (annualised) | 6.2% |
HBIOX Risk Information
Risk metrics for HBIOX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 13.5%
HBIOX Costs and Fees
HBIOX costs about $101 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.01%
- Gross expense ratio: 1.01%
- Portfolio turnover: 43%
- Brokerage commissions: 6.00 bps of average net assets (SEC N-CEN)
HBIOX Cashflows
Over the 12 months to 2026-03, Hartford International Opportunities Hls Fund had net outflows of $199.04M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | −$7.29M |
| 2026-02 | −$13.14M |
| 2026-01 | −$8.30M |
| 2025-12 | −$8.56M |
| 2025-11 | −$8.58M |
| 2025-10 | −$10.70M |
HBIOX Debt Constituents
No individual debt constituents are reported in Hartford International Opportunities Hls Fund's latest SEC N-PORT filing.
HBIOX Prospectus and SEC Filings
Official Hartford International Opportunities Hls Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Developed ex-US Multi-Cap / All-Cap Blend / Core Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.